Shenfu Jianxing Completes Over RMB 300 Million Series Angel Financing Within One Year of Establishment, Aiming to Serve 4 Million Spinal Cord Injury Patients

Unlike the familiar approach of "brain-computer interfaces" represented by Neuralink, which focuses on replacing motor functions, the core of brain-spine interface technology lies inRestoring Neural Pathways Between the Brain and Spinal CordAfter the system is implanted in the patient's body, walking intentions are captured and decoded in real time, bypassing the damaged spinal cord segments and directly relayed to the limbs, thereby enabling intention-controlled walking.

Clinical Validation

In China, there are approximately 4 million patients with spinal cord injury, with around 90,000 new cases annually. For the vast majority, "walking again on their own legs" was once an unattainable dream.

Starting from January 8, 2025, wiraxon, in collaboration with Zhongshan Hospital and Huashan Hospital affiliated with Fudan University, initiated a clinical proof-of-concept study, sequentially performing brain-spine interface therapy on four patients with spinal cord injury who had completely lost motor function. Postoperative data indicate:Within 24 hoursRestore Voluntary Control of Leg MovementAs fast as 7 daysFollowing the achievement of voluntary control over hip and knee joint movements, subjects also exhibited lower extremity sweating, suggesting that neural pathway reconstruction may positively impact the recovery of autonomic nervous function.

China's First Brain-Spine Interface Trial Patient Undergoing Rehabilitation TrainingImage source: @Pujiang Tongzhou

This technology has been grantedU.S. FDA "Breakthrough Device" Designation, making it the first and only technology in China to receive this recognition in the field of invasive brain-computer interfaces.

The FDA Breakthrough Therapy Designation (BTD) is a special review pathway established by the U.S. FDA, focusing on medical devices that “address significant unmet clinical needs” and “possess substantial technological advantages.” It aims to accelerate the research, development, and market approval of new drugs for treating serious or life-threatening diseases, requiring that the drug demonstrate a substantial improvement over existing therapies during early-stage clinical trials. Drugs/products granted entry into this pathway are eligible for intensive FDA guidance, cross-disciplinary collaboration, and accelerated review status, thereby enabling more effective new therapies to reach patients sooner.

Future Plans

The Company will soon initiate a nationwide multi-center registration clinical trial to lay the foundation for subsequent market approval in China and global markets.

According to the strategic plan of founder Dr. Jia Fumin, Wiraxon aims toDrive Clinical Adoption of Core Products and Launch New Production Lines in 2026, and simultaneously initiated the research and development of wearable bionic robots. In an interview with “Innovation Yangpu”, Jia Fumin stated, “Our goal for the first generation is to rapidly achieve functional restoration, which is crucial for patients as immobility following paralysis can lead to numerous complications. However, if patients can still move after removing this device, I believe that would represent the ultimate brain-spine interface technology.”

Group photo of Jia Fumin (6th from left) and his team, the Zhongshan Hospital joint team, and patients. Image source: @Pujiang Tongzhou

A more ambitious vision is to host a global 100-meter race for spinal cord injury patients by 2030, "enabling more spinal cord injury patients to no longer rely on wheelchairs, but to achieve 'free running' with their own legs."

Timeline Overview